Drug Approval | March 22, 2022
Merck’s Keytruda approved for fourth gynecologic cancer indication
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
The medicine is now approved for eight indications across five different types of cancer in China.
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Sales reflect continued strong growth in oncology and vaccines
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)